2016

Parkinson's New Zealand provides information, education and support to people living with Parkinson's, care partners and healthcare professionals. Parkinson's is a progressive neurological condition which affects over 12,000 New Zealanders. Although it cannot be cured, treatment is available.

Dr Matthew Phillips is an expert on ketosis and in this presentation he discusses recent studies and the impact ketosis has on Parkinson's. This very inform...

(NaturalHealth365) New research shows poor oral health and harmful mouth bacteria are linked to chronic pain conditions including migraines.

Explore the real science behind childhood vaccines, long-term safety, immune system health, autism, pharma bias, adjuvants, and personalized pediatric care w...

OmegaXL is a powerful natural supplement shown in clinical research to support joint comfort and function? It contains more than 30 healthy fatty acids, including DHA and EPA. Give it a try, OmegaXL works!

(NaturalHealth365) Shocking new report finds toxic heavy metals in all rice samples tested nationwide. Learn about ways to reduce exposure.

🧠 Stay ahead with the latest in science, nutrition, and wellness by subscribing to Dr. Perlmutter’s newsletter at: www.drperlmutter.com. ✉️🌱The ketogenic d...

This channel is dedicated to helping Persons with Parkinson's Disease to become Parkinson's Warriors fighting their disease wielding the weapon of knowledge about PD and the impact that it has on daily living. Book 1:1 consultation with a Parkinson's Disease Expert here: https://clarity.fm/pdeducation Explore channel memberships here: YouTube: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join Patreon: https://www.patreon.com/pdeducation If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013

PDF | AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical... | Find, read and cite all the research you need on ResearchGate

This is a flowchart on seizures and epilepsy, covering the etiology, pathophysiology, and manifestations. ADDITIONAL TAGS: Atonic seizure ("drop attack"):Non...

Because the data say RB-190 should work.

Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.

Right Brain Bio is developing a data-driven treatment for Parkinson's - one so revolutionary that it will transform disease understanding and treatment.

Dr. Gilbert discusses the seven new medications that were approved to treat Parkinson’s disease motor symptoms since 2017

Exploring Ivermectin’s Neuromodulatory Role in Enhancing Parkinson’s Treatment

Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wa...

May's Open Thread

Cerebral glucose and insulin metabolism is impaired in Alzheimer's disease (AD). Ketones provide alternative energy. Will medium chain triglyceride (MCT) oil, a nutritional source of ketones, impact cognition in AD? This was a 6‐month randomized, ...